Ян Кимаковский - Повышенный холестерин. Профилактика и лечение астеросклероза

72. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004 Mar; 173 (1): 55–68.

73. Кухарчук В. В., Малышев П. П., Мешков А. Н. Семейная гиперхолестеринемия: современные аспекты диагностики, профилактики и терапии. Кардиология. 2009; 49 (1): 76–83.

74. Yuan G, Wang J., Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ. 2006 Apr 11; 174 (8): 1124-9.

75. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on FamilialHypercholesterolemia. J Clin Lipidol. 2011 Jun; 5 (3 Suppl): S9-17.

76. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 1993 Dec; 104 (1–2): 1-18.

77. Merino-Ibarra E., Castillo S., Mozas P., Cenarro A., Martorell E., Díaz JL, Suarez-Tembra M., Alonso R., Civeira F., Mata P., Pocoví M.. Screening of APOB gene mutations in subjects with clinical diagnosis of familialhypercholesterolemia. Hum Biol. 2005 Oct; 77 (5): 663-73.

78. Soufi M., Sattler AM, Maerz W., Starke A., Herzum M., Maisch B., Schaefer JR. A new but frequent mutation of apoB-100-apoB His3543Tyr. Atherosclerosis. 2004 May; 74 (1): 11.

79. Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev. 2008 Feb; 29 (1): 11-2.

80. Мандельштам, М. Ю., Васильев В. Б. Моногенные гиперхолестеринемии: новые гены, новые мишени для лечения. Генетика. – 2008. – Т. 44, N 10. – С. 1309–1316.

81. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA. 2005 Feb 8; 102 (6): 2069-74.

82. Ouguerram K., Chetiveaux M., Zair Y., Costet P., Abifadel M., Varret M., Boileau C., Magot T., Krempf M.. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol. 2004 Aug; 24 (8): 1448-53.

83. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In Scriver CR, Beaudet AL, Sly WS, Valle D. eds, The Metabolic and Molecular Bases of Inherited Disease, 8th ed. New York: McGraw-Hill Information Services Company; 2001, p2863 – 2913.

84. Abifadel M., Rabès JP, Devillers M., Munnich A., Erlich D., Junien C., Varret M., Boileau C. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009 Apr; 30 (4): 520-9.

85. Sharifi M., Futema M., Nair D., Humphries SE. Genetic Architecture of Familial Hypercholesterolaemia. Curr Cardiol Rep. 2017 May; 19 (5): 44.

86. Мешков А. И., Ершова А. И., Щербакова Н. В., Рожкова Т. А., Калинина М. В., Малышев П. П., Кухарчук В. В., Бойцов С. А. Фенотипические особенности течения гетерозиготной формы семейной гиперхолестеринемии у носителей мутаций генов LDLR и APOB. Кардиоваскулярная терапия и профилактика 2011; 10 (8): 63–65.

87. Кухарчук В. В. Этиология и патогенез атеросклероза // Руководство по атеросклерозу и ишемической болезни сердца. Под ред. акад. Е. И. Чазова, член-корр. РАМН В. В. Кухарчука, проф. С. А. Бойцова. М.: Медиа Медика, 2007. – 736 с.

88. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L., Descamps OS, Wiklund O., Hegele RA, Raal FJ, Defesche JC, Wiegman A., Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C., Averna M, Borèn J., Bruckert E., Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E., Taskinen MR, Tybjærg-Hansen A.; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec; 34 (45): 3478-90a. Sijbrands EJ, Westendorp RG, Paola Lombardi M, Havekes LM, Frants RR, Kastelein JJ, Smelt AH. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis. 2000 Apr; 149 (2): 421-5.

89. Sijbrands EJ, Westendorp RG, Paola Lombardi M, Havekes LM, Frants RR, Kastelein JJ, Smelt AH. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis. 2000 Apr; 149 (2): 421-5.

https://ru.iherb.com/pr/Solgar-Taurine-500-mg-250-Vegetable-Capsules/12182?rcode=AVK9750.